



25146-Review

Quotes Excluded
Bibliography Excluded10%
SIMILAR

Match Overview



1	CrossCheck 95 words Kishina, Manabu, Masahiko Koda, Jun Kato, Shiho Tokunaga, Tomomitsu Matono, Takaaki Sugihara, Masaru Ueki, a	2%
2	Internet 90 words crawled on 23-Apr-2016 spandidos-publications.com	2%
3	CrossCheck 34 words "Abstracts of the 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japan", Hepatology International	1%
4	CrossCheck 20 words Sugihara, Takaaki, Masahiko Koda, Manabu Kishina, Jun Kato, Shiho Tokunaga, Tomomitsu Matono, Masaru Ueki,	1%
5	CrossCheck 17 words Koda, Masahiko. "Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohep...	<1%
6	CrossCheck 17 words Matsumoto, M.. "Succinate Increases in the Vitreous Fluid of Patients With Active Proliferative Diabetic Retinopathy",	<1%

Name of Journal: *World Journal of Hepatology*

ESPS Manuscript NO: 25146

Manuscript Type: ORIGINAL ARTICLE

Basic Study

Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model

Toshiaki Okamoto, Masahiko Koda, Kennichi Miyoshi, Takumi Onoyama, Manabu Kishina, Tomomitsu Matono, Takaaki Sugihara, Keiko Hosho, Jun-ichi Okano, Hajime Isomoto, Yoshikazu Murawaki

[全部](#)[图片](#)[新闻](#)[视频](#)[更多 ▾](#)[搜索工具](#)

获得 7 条结果 (用时 0.57 秒)

[\[PDF\] poster session - AIM Group International](#)

web.aimgroupinternational.com/2014/.../wp.../01/poster.pdf ▾ [翻译此页](#)

J. Zochling, J. Sahhar, P. Nash, S. Lester, C. Hill, ... DEPENDENT MURINE MODEL OF SCLERODERMA ... TYPE 1 AND ENDOTHELIN TYPE A RECEPTORS ... IMPACT OF MALE SEX ON SURVIVAL IN SYSTEMIC ... PREDICTION OF WORSENING OF SKIN FIBROSIS ... ANTI IL-6 RECEPTOR ANTAGONIST FOR THE.

[increasing hepatic arterial: Topics by Science.gov](#)

www.science.gov/topicpages/i/increasing+hepatic+arterial.html

Hepatic arteriography and direct portal phlebography were performed on all animals

Background The mouse model of arterialized orthotopic liver transplantation

RESULTS A total of 13 patients (seven males/six females) with a mean age of

Spontaneous Rupture of the Hepatic Artery in a Patient with Type 1

[Patent US9115141 - Substituted isoquinolinones and ...](#)

<https://www.google.com/patents/US9115141>

2015年8月25日 - The term "agonist" as used herein refers to a compound or agent ... The specific dose will vary depending on, for example, the particular (2008) 294:L152-

L160), a variety of liver/biliary fibrosis models (see Chuang et al., Clin Liver Dis

pravastatin); an endothelin receptor antagonist (e.g., Bosentan®); ...

[Patent US9056877 - Heterocyclic compounds and uses ...](#)



Anti-fibrotic effects of endothelin-A receptor antagonist, ambrisentan, in non-a



全部

新闻

图片

视频

更多 ▾

搜索工具

找到约 3,870 条结果 (用时 0.85 秒)

Google 学术: Anti-fibrotic effects of endothelin-A receptor antagonist, ambrisentan, in non-alcoholic steatohepatitis model mice

Evolving therapies for liver fibrosis - Schuppan - 被引用次数: 189

Current status of novel antifibrotic therapies in patients ... - Cohen-Naftaly - 被引用次数: 89

Liver fibrosis - NCBI - National Institutes of Health

www.ncbi.nlm.nih.gov > ... > PubMed Central (PMC) ▾ 翻译此页

作者: R Bataller - 2005 - 被引用次数: 3204 - 相关文章

Advanced liver **fibrosis results** in cirrhosis, liver failure, and portal ... include chronic HCV infection, alcohol abuse, and **nonalcoholic steatohepatitis** (NASH). ... Experimental **models** for studying liver fibrogenesis in rats and in transgenic **mice** were An oral **endothelin-A receptor antagonist** blocks collagen synthesis and ...

缺少字词: ~~ambrisentan~~

Advances in Anti-fibrotic Therapy - NCBI - National Institutes ...

www.ncbi.nlm.nih.gov > ... > PubMed Central (PMC) ▾ 翻译此页

作者: Z Ghiassi-Nejad - 2008 - 被引用次数: 68 - 相关文章

Interesting, **mice** genetically deficient in lecithin:retinol acyltransferase (LRAT) lack There is strong support for the **anti-fibrotic effect** of HGF in animal **models** of fibrosis: Bosentan, a mixed **endothelin A & B receptor antagonist**, has **Anti-fibrotic** Long-term follow-up of patients with **NAFLD** and elevated liver enzymes.

缺少字词: ~~ambrisentan~~

to the clinic for treatment of fibrosis diseases - Nature

www.nature.com/ncd/journal/v14/n10/figs/ncd1502_T1.html ▾ 翻译此页

[全部](#)[新闻](#)[图片](#)[视频](#)[更多 ▾](#)[搜索工具](#)

找到约 625 条结果 (用时 0.79 秒)

Google 学术: Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model

[Current status of novel antifibrotic therapies in patients ...](#) - Cohen-Naftaly - 被引用次数: 99

[Evolving therapies for liver fibrosis](#) - Schuppan - 被引用次数: 205

Progression of selected small molecules[ast] to the clinic for treatment ...

www.nature.com/nrd/journal/v14/n10/fig_tab/nrd4592_T1.html ▾ 翻译此页

2015年9月4日 - **Ambrisentan** is not effective in the treatment of IPF, • IPF (Phase III, terminated ...

Clinical data do not support the use of ET **receptor antagonists** as a therapy ... in **animal models** of NASH (Zydus Cadila company website), • **NAFLD** ... Selective inhibition of JNK exerted potent **anti-fibrotic effects** in vitro and in ...

Dissecting fibrosis: therapeutic insights from the small-molecule ...

www.nature.com/nrd/journal/v14/n10/abs/nrd4592.html ▾ 翻译此页

作者: CB Nanthakumar - 2015 - 被引用次数: 10 - 相关文章

2015年9月4日 - Long-term efficacy of rosiglitazone in **non-alcoholic steatohepatitis: results** of the fatty

The authors highlight the need to evaluate compounds in this **animal model** once fibrosis is Treatment of idiopathic pulmonary fibrosis with **ambrisentan**. ... fibrosis and the **effect** of an **endothelin receptor antagonist**.

Selective endothelin A receptor antagonism with sitaxentan reduces ...

www.ncbi.nlm.nih.gov/pubmed/25598351 ▾ 翻译此页

作者: KM Duthie - 2015 - 被引用次数: 1 - 相关文章

2015年4月23日 - Selective **endothelin A receptor antagonism** with sitaxentan reduces neointimal lesion size in a **mouse model** of intraluminal injury. ... KEY RESULTS: Sitaxentan produced a selective, ...